W.L. Gore and Associates announced the FDA has granted a new indication for prevention of recurrent ischemic stroke for its patent foramen ovale closure device. The expanded approval of the device ...

FLAGSTAFF, Ariz. Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc.

CAUTION: Investigational device. Limited by United States law to investigational use. The Gore RELIEF Clinical Study is evaluating the safety and efficacy of transcatheter closure of patent foramen ...

CAUTION: Investigational device. Limited by United States law to investigational use. The Gore RELIEF study is evaluating the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) ...

Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...

Whether or not percutaneous closure of patent foramen ovale (PFO) can benefit patients with cryptogenic embolism more than medical therapy depends on the device used, asserts a paper published online ...

The US Food and Drug Administration (FDA) has approved the Gore Cardioform septal occluder for closure of patent foramen ovale (PFO) to prevent recurrent ischemic stroke, the manufacturer, WL Gore & ...

Global PFO Closure Device Market Size was estimated at USD 121.53 million in 2021 and is projected to reach USD 208.00 million by 2028, exhibiting a CAGR of 7.98% during the forecast period. “PFO ...